Single-center study of CHeckpoint inhibitor Optimization based on PK/PD and ADA INvestigations in real-life clinical practice

Primary outcome(s): To reveal an association between exposure to immune checkpoint inhibitors and efficacy/safety in cancer patients.

主要研究终点（Primary outcome(s)）：阐明癌症患者群体中，免疫检查点抑制剂（immune checkpoint inhibitors）暴露情况与治疗疗效、安全性之间的关联。